HONG KONG – Shanghai-based Bioshin Ltd., the Asia-Pacific arm of New Haven, Conn.-based Biohaven Pharmaceutical Holding Co. Ltd., has added $60 million to its war chest via a series A investment.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Biophytis, HDT Bio.

HONG KONG – U.S. listed Chinese biotech company Zai Lab Ltd. has raised $761 million in its secondary listing on the Hong Kong Stock Exchange.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Beijing Biocytogen, Betta, Biohaven, Humanigen, Ilias Biologics, Immvira, Inventisbio, Opthea, Recce, Relief, Shanghai, Zai Lab.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Humanigen, Xwpharma, Zai Lab.

Favorable conditions in China encouraged biotech veterans Jerry Wang, Bing Yan and Lihua Zheng to co-found Anheart Therapeutics Co. Ltd. in November 2018 to focus on oncology. On Monday, the Chinese startup in-licensed a mIDH-1 inhibitor and an AXL inhibitor from Daiichi Sankyo Co. Ltd. to expand its pipeline, less than two years after it obtained the global rights of its first asset, AB-106 (taletrectinib), from the Japanese firm to establish its footing.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Oncoimmune.